Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 8Melanoma 6Colonic Neoplasms 4Rectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Thyroid Neoplasms 1Solid Tumors 1Skin Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neoplasms 1Lymphatic Metastasis 1Leukemia, Hairy Cell 1Hereditary Sensory and Autonomic Neuropathies 1Gastrointestinal Neoplasms 1Disease Progression 1Digestive System Neoplasms 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 5Nivolumab 5selpercatinib 4Iodine-124 4Biopsy 4binimetinib 3Iodine-131 3Cetuximab 3ulixertinib 2trametinib 2pembrolizumab 2omipalisib 2larotrectinib 2defactinib 2dabrafenib 2Surveys and Questionnaires 2Sunitinib 2Radiosurgery 2Ipilimumab 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tipifarnib 1temsirolimus 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × encorafenib × 90 days × Clear all
NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Providence Health & Services

Phase 2 Active not recruiting
24 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡